Evaluation of the Efficacy of 50% Autologous Serum Eye Drops in Different Ocular Surface Pathologies

Table 2

Summary of the 26 eyes treated with autologous serum eye drops.

Eye	Sex	Age (y)	Etiology	Weeks of serum therapy	Comorbidity
1	M	41	CB	24	None
2	M	22	CB	24	None
3	M	59	CB	12	None
4	F	81	CB	12	Diabetes mellitus
5	M	29	CB	24	None
6	M	41	CB	12	None
7	M	30	CB	48	None
8	M	32	CB	12	None
9	M	38	CB	12	None
10	M	55	CB	12	None
11	M	31	CB	12	None
12	M	50	CB	24	None
13	M	19	CB	24	None
14	M	23	CB	12	None
15	M	43	CB	12	None
16	F	71	SS	24	None
17	F	37	NK	24	s/p PK
18	F	64	NK	12	s/p trabeculectomy
19	M	71	DE	12	None
20	M	80	DE	24	None
21	M	60	NK	12	Trigeminal neuralgia
22	F	79	SS	48	None
23	F	44	NK	48	s/p trabeculectomy
24	M	37	NK	72	Acoustic neuroma
25	F	40	NK	12	None
26	F	51	NK	48	Lagophthalmos

CB = chemical burn; DE = dry eye syndrome; NK = neurotrophic keratopathy; s/p PK = status postpenetrating keratoplasty; s/p trabeculectomy = status posttrabeculectomy; SS = Sjogren’s syndrome.